Joachim Gullbo, MD
Theradex Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joachim Gullbo, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:12 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04638309 · APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)Aprea Therapeutics · terminated · MDS, Myelodysplastic Syndromes · study director
- Ph1/Ph2NCT04419389 · APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)Aprea Therapeutics · terminated · Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma · study director
- Ph1/Ph2NCT04383938 · Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesAprea Therapeutics · completed · Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.